# Vanda Pharmaceuticals Q4 Earnings Call Highlights

- URL: https://theranews.net/blog/2026-02-12-vanda-pharmaceuticals-q4-earnings-call-highlights-8af1a6/
- Published: 2026-02-12
- Type: Archive summary (AI-assisted summary of third-party reporting)
- Original outlet: thelincolnianonline
- Original report: https://www.thelincolnianonline.com/2026/02/11/vanda-pharmaceuticals-q4-earnings-call-highlights.html
- Topics: anxiety
- Publisher: TheraNews, operated by AdvancedCare USA Inc.
- Notice: Educational content, not medical, legal, billing or financial advice. Cite the original outlet, not this summary.

> Vanda Pharmaceuticals (NASDAQ:VNDA) highlighted strong growth for its lead product Fanapt and detailed several late-stage regulatory and clinical milestones during its fourth-quarter and full-year 2025 earnings call, while also reporting a sharply wider net loss driven largely by a one-time, non-cas

---
![Vanda Pharmaceuticals Q4 Earnings Call Highlights](/uploads/news-images/vanda-pharmaceuticals-q4-earnings-call-highlights-20260212170054.jpg)

---
*Originally reported by thelincolnianonline. [Read more](https://www.thelincolnianonline.com/2026/02/11/vanda-pharmaceuticals-q4-earnings-call-highlights.html)*

---

*Source: [https://www.thelincolnianonline.com/2026/02/11/vanda-pharmaceuticals-q4-earnings-call-highlights.html](https://www.thelincolnianonline.com/2026/02/11/vanda-pharmaceuticals-q4-earnings-call-highlights.html)*